Novartis shares plunge after trial misses primary goal
Novartis said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial. Shares slid 10% shortly after the opening bell Tuesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.